FY2024 EPS Forecast for Immix Biopharma Decreased by Analyst

Immix Biopharma, Inc. (NASDAQ:IMMX) – Equities researchers at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of Immix Biopharma in a research note issued to investors on Monday, January 6th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.87) per share for the year, down from their previous forecast of ($0.67). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.85) EPS.

Immix Biopharma Stock Performance

Shares of Immix Biopharma stock opened at $2.25 on Thursday. Immix Biopharma has a fifty-two week low of $1.26 and a fifty-two week high of $6.67. The firm has a market capitalization of $61.89 million, a price-to-earnings ratio of -2.65 and a beta of 0.27. The stock has a 50 day moving average of $2.01 and a 200 day moving average of $1.95.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08).

Institutional Trading of Immix Biopharma

A hedge fund recently raised its stake in Immix Biopharma stock. Geode Capital Management LLC lifted its stake in Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 150,082 shares of the company’s stock after acquiring an additional 7,954 shares during the quarter. Geode Capital Management LLC owned 0.55% of Immix Biopharma worth $224,000 at the end of the most recent reporting period. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.